Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
$0.72
$0.72
$0.55
$1.45
$23.72M-0.57483,585 shsN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$2.26
-5.0%
$2.44
$1.62
$14.67
$5.36M1.09927,962 shs49,552 shs
KALA BIO, Inc. stock logo
KALA
KALA BIO
$3.80
-6.4%
$4.09
$2.92
$11.20
$24.52M-1.9193,670 shs32,013 shs
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$9.09
+17.4%
$6.30
$1.72
$10.40
$33.18M1.38132,939 shs76,079 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
0.00%0.00%0.00%-6.29%-46.62%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
+8.18%-1.65%-27.66%-55.84%-72.16%
KALA BIO, Inc. stock logo
KALA
KALA BIO
+0.50%+2.78%+27.67%-39.49%-37.63%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
+13.66%+20.19%+15.35%-4.91%+309.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.2181 of 5 stars
0.02.00.00.03.30.00.0
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.4013 of 5 stars
3.51.00.04.42.50.00.6
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.5127 of 5 stars
0.05.00.00.02.20.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
2.33
Hold$0.9531.83% Upside
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.00
N/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.00
Buy$13.50255.26% Upside
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ENSC, PULM, CYTH, and KALA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/23/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
4/4/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
$870.73K27.24N/AN/A$0.21 per share3.43
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$2.23M2.40N/AN/A($3.10) per share-0.73
KALA BIO, Inc. stock logo
KALA
KALA BIO
$3.89M6.30N/AN/A$2.79 per share1.36
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$1.92M17.27N/AN/A$4.93 per share1.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
-$20.06M-$0.90N/AN/AN/A-2,847.19%N/A-307.16%N/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$10.61M-$6.54N/AN/AN/A-179.26%-292.81%-158.83%8/13/2025 (Estimated)
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$42.20M-$8.24N/AN/AN/AN/A-448.61%-69.37%8/5/2025 (Estimated)
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-$14.12M-$3.34N/AN/A-96.51%-45.97%-30.72%8/11/2025 (Estimated)

Latest ENSC, PULM, CYTH, and KALA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A-$0.50N/A-$0.50N/AN/A
5/13/2025Q1 2025
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 million
3/28/2025Q4 2024
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$2.28-$1.74+$0.54-$1.74N/AN/A
3/21/2025Q4 2024
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A-$0.54N/A-$0.54N/AN/A
3/10/2025Q4 2024
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$2.74-$2.90-$0.16-$2.90$0.25 million$1.30 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
N/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/AN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
N/A
0.17
0.16
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
3.24
3.24
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.18
2.15
2.15
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A
19.40
19.40

Institutional Ownership

CompanyInstitutional Ownership
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
68.55%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
5.63%
KALA BIO, Inc. stock logo
KALA
KALA BIO
24.61%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
11.84%

Insider Ownership

CompanyInsider Ownership
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
29.78%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
7.90%
KALA BIO, Inc. stock logo
KALA
KALA BIO
8.32%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
932.92 million23.12 millionNo Data
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
102.37 million1.20 millionNot Optionable
KALA BIO, Inc. stock logo
KALA
KALA BIO
306.45 million5.58 millionNot Optionable
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
203.65 million3.63 millionNot Optionable

Recent News About These Companies

How to Take Advantage of moves in (PULM)
When the Price of (PULM) Talks, People Listen
Pulmatrix Inc.: Pulmatrix and Cullgen Announce Proposed Merger

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cyclo Therapeutics stock logo

Cyclo Therapeutics NASDAQ:CYTH

$0.72 0.00 (0.00%)
As of 03/26/2025

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$2.26 -0.12 (-5.04%)
Closing price 04:00 PM Eastern
Extended Trading
$2.23 -0.03 (-1.28%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

KALA BIO stock logo

KALA BIO NASDAQ:KALA

$3.80 -0.26 (-6.40%)
Closing price 04:00 PM Eastern
Extended Trading
$3.80 0.00 (-0.03%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Pulmatrix stock logo

Pulmatrix NASDAQ:PULM

$9.09 +1.35 (+17.44%)
Closing price 04:00 PM Eastern
Extended Trading
$9.05 -0.04 (-0.48%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.